Gender Specific Association of RAS Gene Polymorphism with Essential Hypertension: A Case-Control Study

Table 4

Distribution of RAS gene polymorphisms (dominant and recessive model) in patient and control subjects.

SNPs	Model	TEST	Case (𝑁)	Control (𝑁)	OR	95% CI	𝑃 value
AGT M235T	MM + MT versus TT	DOM	94/117	108/103	0.766	0.513–1.144	0.173
	MM versus MT + TT	REC	13/198	30/181	0.396	0.184–0.813	𝟎.𝟎𝟎𝟔^∗
Male	MM + MT versus TT	DOM	52/57	64/66	0.941	0.547–1.616	0.814
	MM versus MT + TT	REC	9/100	16/114	0.641	0.239–1.624	0.308
Female	MM + MT versus TT	DOM	42/60	44/37	0.589	0.313–1.106	0.077
	MM versus MT + TT	REC	04/98	14/67	0.062	0.015–0.185	0.000
ACE I/D	II + ID versus DD	DOM	128/83	144/67	0.718	0.471–1.092	0.104
	II versus ID + DD	REC	40/171	51/160	0.734	0.447–1.201	0.193
Male	II + ID versus DD	DOM	59/50	97/33	0.401	0.224–0 .718	𝟎.𝟎𝟎𝟎𝟗^∗
	II versus ID + DD	REC	19/90	30/100	0.704	0.349–1.397	0.282
Female	II + ID versus DD	DOM	69/33	47/34	1.513	0.789–2.898	0.180
	II versus ID + DD	REC	21/81	21/60	0.741	0.350–1.569	0.394
ACE G2350A	AA + AG versus GG	DOM	61/150	58/153	1.073	0.686–1.677	0.746
	AA versus AG + GG	REC	12/199	11/200	1.096	0.432–2.813	0.830
Male	AA + AG versus GG	DOM	31/78	29/101	1.384	0.738–2.596	0.276
	AA versus AG + GG	REC	7/102	6/124	1.418	0.394–0.273	0.540
Female	AA + AG versus GG	DOM	30/72	29/52	0.747	0.383–1.462	0.358
	AA versus AG + GG	REC	05/97	05/76	0.784	0.174–0.542	0.707
A1166C	CC + CT versus TT	DOM	123/88	126/85	0.943	0.628–1.416	0.767
	CC versus CT + TT	REC	39/172	43/168	0.886	0.530–1.477	0.623
Male	CC + CA versus AA	DOM	68/41	77/53	1.142	0.656–1.992	0.619
	CC versus CA + AA	REC	20/89	25/105	0.944	0.464–1.903	0.862
Female	CC + CA versus AA	DOM	55/47	49/32	0.764	0.405–1.439	0.373
	CC versus CA + AA	REC	19/83	18/63	0.801	0.365–1.767	0.548

DOM: dominant model; REC: recessive model; 𝑁: sample size; OR: odds ratio; CI: confidence interval; ^∗𝑃<0.05: statically significant.